Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVE0675
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
AVE0675 is a Toll-like receptor 7 (TLR7) agonist that was developed for the treatment of allergic asthma. Discovered by Coley Pharmaceutical Group and licensed to Sanofi-Aventis in 2005, the drug was designed to modulate the immune response by stimulating TLR7, which is primarily expressed on plasmacytoid dendritic cells and B cells. Activation of this receptor induces the secretion of Type I interferons and Th1-type cytokines, thereby redirecting the immune system away from the Th2-driven allergic response that characterizes asthma. The program was discontinued during early clinical development following Phase 1 trials.
02
Targets
TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on AVE0675.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVE0675.